Investor Centre
Our pipeline and lead compound SFX-01 is derived from our proprietary Sulforadex® technology.
0.83 GBX
Volume:
195,000
Market Capitalisation (m)
£3.53
Corporate Presentation
Acquisition, Fundraising and Change of Name
19 - March - 2024Evgen announces the acquisition of Chronos Therapeutics, placing and subscription offer and company name change.
Investor Meet Presentation – Proposed Acquisition of Chronos Therapeutics Ltd, Placing and Accompanying Retail Offer
21 - March - 2024CEO Dr Huw Jones, CBO Dr Helen Kuhlman and new CFO Toni Haenninen discuss Evgen's proposed acquisition of Chronos Therapeutics Ltd.
| Company | Analyst |
|---|---|
| Cavendish | Mark Brewer |
Major Shareholder
| Current Shareholder | Number of shares | Percentage holding |
|---|---|---|
| J. R. Kight | 33,100,000 | 12.0% |
| Octopus Investments | 21,875,000 | 8.0% |
| SPARK Impact | 16,186,446 | 5.9% |
| Seneca Investment Managers | 14,932,071 | 5.4% |
| AXA Framlington | 13,399,724 | 4.87% |
| Chelverton Asset Management | 12,500,000 | 4.5% |
| RAB Capital | 8,750,000 | 3.2% |
| Newlands Capital | 8,314,815 | 3.0% |
The number of ordinary shares in issue is 274,888,117 all of which are in public hands. The Company does not hold any shares in Treasury.
